10x Genomics: Kim Popovits
10x Genomics has appointed Kim Popovits to its board of directors. Popovits is the former chairman, president, and CEO of Genomic Health. She started at Genomic Health in 2002 as president and chief operating officer, before becoming CEO in 2009 and chairman in 2012. The company was acquired by Exact Sciences in November 2019.
Prior to joining Genomic Health, Popovits held several management roles at Genentech, including senior vice president of marketing and sales where she led the commercialization of 14 new therapies. In addition to her board position at 10x Genomics, Popovits is currently a member of the boards of Kiniksa Pharmaceuticals and MyoKardia, and previously served on the board of ZS Pharma.
Castle Biosciences: Miles Harrison
Castle Biosciences has appointed Miles Harrison to its board of directors effective immediately, expanding the size of the board to eight members. Harrison will stand for election for a three-year term at the company's 2020 annual meeting of stockholders.
Since February 2016, Harrison as served as the North American president and general manager of independent global dermatology company Galderma Laboratories. He has also served as vice president and general manager of Galderma's consumer business unit. Prior to Galderma, Harrison spent most of his career at Novartis, and has held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy.
Biotheranostics: Matt Sargent
Biotheranostics has promoted its vice president of sales, Matt Sargent, to the position of chief commercial officer. In his new role, Sargent will be responsible for sales, marketing, market access, and customer service, and will lead the company's growth of its core tests: Breast Cancer Index and CancerTYPE ID. Sargent holds over 17 years of experience in the oncology diagnostic space during which he led the launch of Breast Cancer Index at Biotheranostics and the launch of the oncology division of Caris Life Sciences, where he served as vice president of oncology sales.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.